Screener
LB Pharmaceuticals Inc LBRX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Realized gain on sale of marketable securities, net | — | 119 |
| Gain on change in fair value of derivative instruments | 200 | 768 |
| Total non-operating income | 3,050 | 1,123 |
| Loss before income tax | (19,054) | (5,306) |
| Income tax provision | — | — |
| Net loss | $(19,054) | $(5,306) |
| Net loss per share, basic and diluted | $(0.67) | $(14.79) |
| Weighted average shares outstanding used in calculating net loss per share, basic and diluted | 28,241,701 | 358,777 |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's net income?
- LB Pharmaceuticals Inc (LBRX) reported net income of -$19.05M in Q1 2026.
- How has LB Pharmaceuticals Inc's net income changed year-over-year?
- LB Pharmaceuticals Inc's net income decreased by 259.1% year-over-year, from -$5.31M to -$19.05M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about LB Pharmaceuticals Inc's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude